Researchers at Stanford have developed an IL-7–conjugated lipid nanoparticle (LNP) platform designed to substantially improve mRNA delivery to T cells for direct in vivo T-cell engineering.
Stanford researchers have developed a label-free platform that combines surface-enhanced Raman spectroscopy (SERS) with machine learning to enable rapid, non-destructive profiling of cell identity and functional state at single-cell resolution.
Hematological cancers like non-Hodgkin's lymphoma have seen a revolution in care due to the advances of targeted cell therapies like CAR-T. However, not all blood cancers have enjoyed the same benefit, hampered by the lack of actionable and specific blood cell targets.
Stanford researchers have developed the Broadly Usable Multi-Pass Engineered Receptor (BUMPER) architecture, a novel protein engineering platform for assembling stable, multifunctional cell surface receptors.
Stanford scientists have developed species cross-reactive B7H3-targeting CAR-T cells that can effectively target both human and mouse tumors, enabling more accurate preclinical testing in immunocompetent models.
Stanford scientists have developed the Programmable Antigen-Mediated Cellular Knock-in of T cell (PACK-IT) platform that enables rapid CAR-T cell engineering in hours rather than weeks.
Stanford scientists have developed a method to selectively expand CAR-T cells by co-delivering IL9R with CAR genes using a novel platform that enables rapid CAR-T cell engineering through targeted lentiviral delivery.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford scientists have developed a trivalent CAR T cell that targets three proteins that are essential for self-renewal and differentiation of leukemic stem cells.
Stanford researchers have developed a non-viral, homology-independent method for precise targeted DNA insertions into T-cells using electroporation and CRISPR/Cas9, enabling cost-effective production of CAR T-cells for T-cell therapies.
Researchers in Prof. Crystal Mackall's laboratory at Stanford University are focused on translational research related to cancer immunotherapy, including basic T-cell function and tumor immunology.
Stanford researchers have engineered chimeric cytokine receptors that are expressed in therapeutic cells to enhance their activity and therapeutic potential.
Many applications in cell therapy, synthetic biology, and gene therapy require extensive cell engineering, often with multiple vectors due to limitations in packaging capacity.